Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis

NCT06644638 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT06644638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06644638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
Lead sponsor
Novartis
Phase
Observational
Overall status
Completed
Start date
February 15, 2023
Completion date
October 30, 2023
Enrollment
3,632 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis